Europe PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Country and Growth Forecast, 2024 - 2031

The Europe PARP Inhibitor Biomarkers Market would witness market growth of 8.1% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $92 Million by 2031. The UK market is exhibiting a CAGR of 7.1% during (2024 - 2031). Additionally, The France market would experience a CAGR of 8.9% during (2024 - 2031).

The rising incidence of various cancer types, including breast, ovarian, prostate, and pancreatic cancer, is driving the demand for effective treatment options. PARP inhibitors have shown promising results in clinical trials and have been approved to treat certain cancers.

Moreover, the applications of it are multifaceted, encompassing various aspects of oncology care and precision medicine. For example, one of the primary applications of this is patient selection for this therapy.

The increasing prevalence of cancer in Europe contributes to the expansion of precision oncology practices, which focus on tailoring treatments to individual patients based on their molecular characteristics. these are crucial in guiding treatment decisions by identifying patients with specific DNA repair deficiencies likely to respond to its therapy.

Free Valuable Insights: The Global PARP Inhibitor Biomarkers Market will Hit USD 1.6 Billion by 2031, at a CAGR of 8.3%

Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

• Myriad Genetics, Inc.
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• NeoGenomics Laboratories
• Qiagen N.V
• Agilent Technologies, Inc.
• Merck KGaA
• Bayer AG
• AstraZeneca PLC
• GlaxoSmithKline PLC (GSK)

Europe PARP Inhibitor Biomarkers Market Report Segmentation

By Product

• Kits
• Assays

By Application

• Breast Cancer
• Ovarian Cancer
• Others

By Services

• BRCA 1 & 2 Testing
• HRD Testing
• HRR Testing
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe PARP Inhibitor Biomarkers Market, by Product
1.4.2 Europe PARP Inhibitor Biomarkers Market, by Application
1.4.3 Europe PARP Inhibitor Biomarkers Market, by Services
1.4.4 Europe PARP Inhibitor Biomarkers Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis

Chapter 4. Europe PARP Inhibitor Biomarkers Market by Product
4.1 Europe Kits Market by Country
4.2 Europe Assays Market by Country

Chapter 5. Europe PARP Inhibitor Biomarkers Market by Application
5.1 Europe Breast Cancer Market by Country
5.2 Europe Ovarian Cancer Market by Country
5.3 Europe Others Market by Country

Chapter 6. Europe PARP Inhibitor Biomarkers Market by Services
6.1 Europe BRCA 1 & 2 Testing Market by Country
6.2 Europe HRD Testing Market by Country
6.3 Europe HRR Testing Market by Country
6.4 Europe Others Market by Country

Chapter 7. Europe PARP Inhibitor Biomarkers Market by Country
7.1 Germany PARP Inhibitor Biomarkers Market
7.1.1 Germany PARP Inhibitor Biomarkers Market by Product
7.1.2 Germany PARP Inhibitor Biomarkers Market by Application
7.1.3 Germany PARP Inhibitor Biomarkers Market by Services
7.2 UK PARP Inhibitor Biomarkers Market
7.2.1 UK PARP Inhibitor Biomarkers Market by Product
7.2.2 UK PARP Inhibitor Biomarkers Market by Application
7.2.3 UK PARP Inhibitor Biomarkers Market by Services
7.3 France PARP Inhibitor Biomarkers Market
7.3.1 France PARP Inhibitor Biomarkers Market by Product
7.3.2 France PARP Inhibitor Biomarkers Market by Application
7.3.3 France PARP Inhibitor Biomarkers Market by Services
7.4 Russia PARP Inhibitor Biomarkers Market
7.4.1 Russia PARP Inhibitor Biomarkers Market by Product
7.4.2 Russia PARP Inhibitor Biomarkers Market by Application
7.4.3 Russia PARP Inhibitor Biomarkers Market by Services
7.5 Spain PARP Inhibitor Biomarkers Market
7.5.1 Spain PARP Inhibitor Biomarkers Market by Product
7.5.2 Spain PARP Inhibitor Biomarkers Market by Application
7.5.3 Spain PARP Inhibitor Biomarkers Market by Services
7.6 Italy PARP Inhibitor Biomarkers Market
7.6.1 Italy PARP Inhibitor Biomarkers Market by Product
7.6.2 Italy PARP Inhibitor Biomarkers Market by Application
7.6.3 Italy PARP Inhibitor Biomarkers Market by Services
7.7 Rest of Europe PARP Inhibitor Biomarkers Market
7.7.1 Rest of Europe PARP Inhibitor Biomarkers Market by Product
7.7.2 Rest of Europe PARP Inhibitor Biomarkers Market by Application
7.7.3 Rest of Europe PARP Inhibitor Biomarkers Market by Services

Chapter 8. Company Profiles
8.1 Myriad Genetics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.2 Thermo Fisher Scientific, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 SWOT Analysis
8.3 Illumina, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segment and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Neogenomics, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 Qiagen N.V.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Agilent Technologies, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Merck KGaA
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 AstraZeneca PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis

TABLE 1 Europe PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 2 Europe PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 3 Europe PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 4 Europe PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 5 Europe Kits Market by Country, 2020 - 2023, USD Million
TABLE 6 Europe Kits Market by Country, 2024 - 2031, USD Million
TABLE 7 Europe Assays Market by Country, 2020 - 2023, USD Million
TABLE 8 Europe Assays Market by Country, 2024 - 2031, USD Million
TABLE 9 Europe PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 10 Europe PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 11 Europe Breast Cancer Market by Country, 2020 - 2023, USD Million
TABLE 12 Europe Breast Cancer Market by Country, 2024 - 2031, USD Million
TABLE 13 Europe Ovarian Cancer Market by Country, 2020 - 2023, USD Million
TABLE 14 Europe Ovarian Cancer Market by Country, 2024 - 2031, USD Million
TABLE 15 Europe Others Market by Country, 2020 - 2023, USD Million
TABLE 16 Europe Others Market by Country, 2024 - 2031, USD Million
TABLE 17 Europe PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 18 Europe PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 19 Europe BRCA 1 & 2 Testing Market by Country, 2020 - 2023, USD Million
TABLE 20 Europe BRCA 1 & 2 Testing Market by Country, 2024 - 2031, USD Million
TABLE 21 Europe HRD Testing Market by Country, 2020 - 2023, USD Million
TABLE 22 Europe HRD Testing Market by Country, 2024 - 2031, USD Million
TABLE 23 Europe HRR Testing Market by Country, 2020 - 2023, USD Million
TABLE 24 Europe HRR Testing Market by Country, 2024 - 2031, USD Million
TABLE 25 Europe Others Market by Country, 2020 - 2023, USD Million
TABLE 26 Europe Others Market by Country, 2024 - 2031, USD Million
TABLE 27 Europe PARP Inhibitor Biomarkers Market by Country, 2020 - 2023, USD Million
TABLE 28 Europe PARP Inhibitor Biomarkers Market by Country, 2024 - 2031, USD Million
TABLE 29 Germany PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 30 Germany PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 31 Germany PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 32 Germany PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 33 Germany PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 34 Germany PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 35 Germany PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 36 Germany PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 37 UK PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 38 UK PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 39 UK PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 40 UK PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 41 UK PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 42 UK PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 43 UK PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 44 UK PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 45 France PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 46 France PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 47 France PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 48 France PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 49 France PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 50 France PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 51 France PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 52 France PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 53 Russia PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 54 Russia PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 55 Russia PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 56 Russia PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 57 Russia PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 58 Russia PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 59 Russia PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 60 Russia PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 61 Spain PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 62 Spain PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 63 Spain PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 64 Spain PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 65 Spain PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 66 Spain PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 67 Spain PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 68 Spain PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 69 Italy PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 70 Italy PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 71 Italy PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 72 Italy PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 73 Italy PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 74 Italy PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 75 Italy PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 76 Italy PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 77 Rest of Europe PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 78 Rest of Europe PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 79 Rest of Europe PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 80 Rest of Europe PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 81 Rest of Europe PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 82 Rest of Europe PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 83 Rest of Europe PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 84 Rest of Europe PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 85 Key Information – Myriad Genetics, Inc.
TABLE 86 Key Information – Thermo Fisher Scientific, Inc.
TABLE 87 key information – Illumina, Inc.
TABLE 88 Key Information – neogenomics, inc.
TABLE 89 Key Information – Qiagen N.V.
TABLE 90 key Information – Agilent Technologies, Inc.
TABLE 91 key Information – Merck KGaA
TABLE 92 Key Information – Bayer AG
TABLE 93 Key Information – AstraZeneca PLC
TABLE 94 Key Information – GlaxoSmithKline PLC

List of Figures
FIG 1 Methodology for the research
FIG 2 Europe PARP Inhibitor Biomarkers Market, 2020 - 2031, USD Million
FIG 3 Key Factors Impacting PARP Inhibitor Biomarkers Market
FIG 4 Porter’s Five Forces Analysis – PARP Inhibitor Biomarkers Market
FIG 5 Europe PARP Inhibitor Biomarkers Market share by Product, 2023
FIG 6 Europe PARP Inhibitor Biomarkers Market share by Product, 2031
FIG 7 Europe PARP Inhibitor Biomarkers Market by Product, 2020 - 2031, USD Million
FIG 8 Europe PARP Inhibitor Biomarkers Market share by Application, 2023
FIG 9 Europe PARP Inhibitor Biomarkers Market share by Application, 2031
FIG 10 Europe PARP Inhibitor Biomarkers Market by Application, 2020 - 2031, USD Million
FIG 11 Europe PARP Inhibitor Biomarkers Market share by Services, 2023
FIG 12 Europe PARP Inhibitor Biomarkers Market share by Services, 2031
FIG 13 Europe PARP Inhibitor Biomarkers Market by Services, 2020 - 2031, USD Million
FIG 14 Europe PARP Inhibitor Biomarkers Market share by Country, 2023
FIG 15 Europe PARP Inhibitor Biomarkers Market share by Country, 2031
FIG 16 Europe PARP Inhibitor Biomarkers Market by Country, 2020 - 2031, USD Million
FIG 17 SWOT Analysis: Thermo Fisher Scientific, Inc.
FIG 18 Swot Analysis: Illumina, Inc.
FIG 19 Swot Analysis: Qiagen N.V.
FIG 20 Swot Analysis: Agilent Technologies, Inc.
FIG 21 Swot Analysis: Merck KGaA
FIG 22 Swot Analysis: Bayer AG
FIG 23 SWOT Analysis: AstraZeneca PLC
FIG 24 SWOT Analysis: GlaxoSmithKline PLC